Endonovo Therapeutics (ENDV) 10-Q/A 15 Jun 15 2015 Q1 Quarterly report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Jun. 15, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	1528172
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		98,797,026

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$25,648	$988
Other current assets		2,000
Total current assets	25,648	2,988
Property Plant and Equipment, net	38,961	42,601
Total Assets	64,609	45,589
Current Liabilities
Accounts payable and accrued expenses	3,411,732	3,167,346
Related party advances	8,655	900
Notes payable	953,001	1,084,025
Notes payable - related party	341,000	291,000
Current portion of long term loan	11,764	11,677
Total current liabilities	4,726,152	4,554,948
Long term loan	25,673	28,646
Acquisition payable	155,000	155,000
Total liabilities	4,906,825	4,738,594
Shareholders' deficit
Common stock, $.0001 par value; 250,000,000 shares authorized; 96,433,466 and 81,425,957 shares issued and outstanding as of March 31, 2015 and December 31, 2014	9,644	8,143
Additional paid-in capital	1,922,740	1,593,297
Stock subscriptions	-1,570	-1,570
Accumulated deficit	-6,773,030	-6,292,875
Total shareholders' deficit	-4,842,216	-4,693,005
Total Liabilities and Shareholders' Deficit	$64,609	$45,589

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	96,433,466	81,425,957
Common stock, shares outstanding	96,433,466	81,425,957

Condensed_Consolidated_Stateme

Condensed Consolidated Statement of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenues, net	$2,745	$17,759
Cost of goods sold	824	8,448
Gross profit	1,921	9,311
Operating expenses	433,554	576,434
Loss from operations	-431,633	-567,123
Other income (expense)
Other income		535
Interest expense, net	-48,522	-61,927
Other income (expense), total	-48,522	-61,392
Loss before income taxes	-480,155	-628,515
Provision for income taxes
Net loss	($480,155)	($628,515)
Basic and diluted loss per share	($0.01)	($0.01)
Weighted average common share outstanding:
Basic and diluted	84,824,577	85,996,385

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating activities:
Net loss	($480,155)	($628,515)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense	3,640	3,175
Fair value of equity issued for services	2,304	4,715
Non-cash amortization of interest	1,766	10,330
Changes in assets and liabilities:
Other current assets	2,000
Inventory		-39,200
Accounts payable and accrued expenses	276,609	453,565
Net cash used in operating activities	-193,836	-195,930
Investing activities:
Net cash used in investing activities
Financing activities:
Proceeds from the issuance of notes payable	212,500	287,000
Proceeds from related party advances	7,755
Proceeds from issuance of common stock	177
Payment against long term loan	-1,936	-3,399
Payment against notes payable- related party		-11,280
Net cash provided by financing activities	218,496	272,321
Net increase in cash	24,660	76,391
Cash, beginning of year	988	3,255
Cash, end of period	25,648	79,646
Supplemental disclosure of cash flow information:
Cash paid for interest		219
Cash paid for income taxes		532
Non Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	$328,138

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) (USD $)	Total	Common Stock	Additional Paid-in Capital	Common Stock Subscription Receivable	Retained Earnings
Beginning balance at Dec. 31, 2014	($4,693,005)	$8,143	$1,593,297	($1,570)	($6,292,875)
Beginning balance, shares at Dec. 31, 2014		81,425,957
Shares issued for cash	177	18	159
Shares issued for cash, shares		177,631
Share issued for services	2,304	230	2,074
Share issued for services, shares		2,304,286
Shares issued with notes payable	325	33	292
Shares issued with notes payable, shares		325,000
Share issued for conversion of notes payable and accrued interest	328,138	1,220	326,918
Share issued for conversion of notes payable and accrued interest, shares		12,200,592
Net loss	-480,155				-480,155
Ending balance at Mar. 31, 2015	($4,842,216)	$9,644	$1,922,740	($1,570)	($6,773,030)
Ending balance, shares at Mar. 31, 2015		96,433,466

Organization_and_Nature_of_Bus

Organization and Nature of Business	3 Months Ended
	Mar. 31, 2015
Organization and Nature of Business [Abstract]
Organization and Nature of Business	Note 1 - Organization and Nature of Business
	Endonovo Therapeutics, Inc. and Subsidiaries (the “Company” or “ETI”) operates in two business segments: 1) intellectual property licensing and commercialization; and 2) biomedical research and development which has included the development of the TVEMF device which has been the source of all revenues in the current year.
	Basis of Presentation and Principles of Consolidation
	The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of March 31, 2015, and 2014 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.
	The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation.
	Going Concern
	These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements.  The Company has raised approximately $212,500 in debt financing for the period January 1, 2015 to March 31, 2015.  The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations.  However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern.  No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from it license agreements, has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies.  Although, uncertainty exists as to whether the Company will be able generate enough cash from operations to fund the Company’s working capital needs or raise sufficient capital to meet the Company’s obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty.
	Recent Accounting Standard Updates
	The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or result of its operations.
	Reclassification
	The 2014 financial statements have been reclassified to conform to the current year presentation.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2015
Property and Equipment [Abstract]
Property and Equipment	Note 2 - Property and Equipment
	The following is a summary of equipment, at cost, less accumulated depreciation at March 31, 2015 and December 31, 2014:
			March		December 31,
			31,
			2015		2014
	Autos	$	64,458	$	64,458
	Medical equipment		5,000		5,000
	Other equipment		4,945		4,945
			74,403		74,403
	Less accumulated depreciation		35,442		31,802
		$	38,961	$	42,601

Notes_Payable_and_Long_Term_Lo

Notes Payable and Long Term Loan	3 Months Ended
	Mar. 31, 2015
Notes Payable and Long Term Loan [Abstract]
Notes Payable and Long Term Loan	Note 3 - Notes Payable and Long Term Loan
	Notes Payable
	In October 2013, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000. The notes bear interest at 10% per annum and are due and payable with accrued interest one year from issuance.  Also, the Company agreed to issue 125,000 shares of its common stock for each unit. In July 2014, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000. The notes bear interest at 10% per annum and are due and payable with accrued interest one year from issuance.  Also, the Company agreed to issue 50,000 shares of its common stock for each unit. In October 2014, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000. The notes bear interest at 10% per annum and are due and payable with accrued interest one year from issuance.  Also, the Company agreed to issue 50,000 shares of its common stock for each unit. From January 1, 2014 to March 31, 2015, the company has issued promissory notes for an aggregate principal of approximately $1,158,000.
			As of
				31-Mar-15			31-Dec-14
	Notes payable at beginning of period		$	1,377,416		$	710,072
	Notes payable issued for cash			212,500			935,500
	Less amounts converted to stock			-295,915			-268,156
	Notes payable at end of period			1,294,001			1,377,416
	Less debt discount			-			-2,391
			$	1,294,001		$	1,375,025
	Notes payable issued to related parties		$	341,000		$	291,000
	Notes payable issued to non-related parties		$	953,001		$	1,086,416
	Long Term Loan
	The Company has financed the purchase of an automobile.  The maturity dates on the loan are as follows:
		Twelve months ending,
		31-Mar-16		$	11,764
		31-Mar-17		$	12,121
		31-Mar-18		$	12,488
		31-Mar-19		$	1,064
				$	37,437
		Current portion		$	11,764
		Long term portion		$	25,673

Shareholders_Deficit

Shareholders' Deficit	3 Months Ended
	Mar. 31, 2015
Shareholders' Deficit [Abstract]
Shareholders' Deficit	Note 4 - Shareholders’ Deficit
	Reverse Spilt
	On April 28, 2014, we concluded the process of changing our corporate name to Endonovo Therapeutics, Inc. and began trading under the symbol ENDV.  The Company enacted a reverse stock split effective May 15, 2014.  All share and per share numbers in this report have been adjusted for the reverse stock split.
	Common Stock
	The Company has entered into consulting agreements with various consultants for service to be provided to the Company. The agreements stipulate a monthly fee and a certain number of shares that the consultant vests in over the term of the contract. The consultant is issued a prorated number of shares of common stock at the beginning of the contract, which the consultant earns over a three-month period. At the anniversary of each quarter, the consultant is issued a new allotment of common stock. In accordance with ASC 505-50 – Equity-Based Payment to Non-Employees, the common stock shares issued to the consultant are valued upon their vesting, with interim estimates of value as appropriate during the vesting period.
	The shares of common stock that have vested through January 2013 were valued based on a valuation performed by an independent valuation firm as the Company had no active market for its shares prior to that time. The Company’s shares began trading in January 2013; as a result the Company utilized market value for its stock when valuing its common stock for the three months ended March 31, 2013. During the second quarter of 2013, the Company revalued the shares based on low trading volume to $0.001. During the three months ended March 31, 2015, the Company granted 2,304,286 shares for services performed by consultants and recorded expense of $2,304.
	During the three months ended March 31, 2015, the Company issued 325,000 shares of common stock to the purchasers of notes.  The share issuance was valued at $325.
	In addition, during the three months ended March 31, 2015, the Company issued 12,200,592 shares of common stock on the conversion of notes in an amount of $295,915 and accrued interest of $32,223.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Note 5 – Related Party Transactions
	From time-to-time officers of the Company advance monies t the Company to cover costs.  During the three months ended March 31, 2015, officers advanced $7,755 of funds to the Company.  No repayments were made during the period.
	As further illustrated in Note 3, officers of the Company have entered into note payable agreements with the Company.  During the quarter ended March 31, 2015, the Company received $50,000 from an officer.  The balance of notes payable from related parties at March 31, 2015 is $341,000.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 6 – Subsequent Events
	From April 1, 2015 through May 12, 2015 an aggregate of 1,695,000 shares of restricted common stock were issued as compensation to independent contractors.
	From April 1, 2015 through May 12, 2015, the Company issued $37,500 in notes payable and issued 75,000 shares of its restricted common stock pursuant to a Private Placement Memorandum and private offerings.
	From April 1, 2015 through May 12, 2015, the Company issued an aggregate of 43,500 shares of its restricted common stock pursuant to Securities Purchase Agreements.
	On May 16, 2015 the Company issued 250,000 shares as part of an extension agreement to Donnie Rudd’s $96,000 Note Payable, which was due and payable on May 15, 2015. As part of the extension, the new due date of the Note is August 15, 2015.
	As a result of these issuances the total number of shares outstanding is 98,497,026.

Organization_and_Nature_of_Bus1

Organization and Nature of Business (Policies)	3 Months Ended
	Mar. 31, 2015
Organization and Nature of Business [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation
	The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of March 31, 2015, and 2014 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.
	The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation.
Going Concern	Going Concern
	These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements.  The Company has raised approximately $212,500 in debt financing for the period January 1, 2015 to March 31, 2015.  The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations.  However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern.  No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from it license agreements, has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies.  Although, uncertainty exists as to whether the Company will be able generate enough cash from operations to fund the Company’s working capital needs or raise sufficient capital to meet the Company’s obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty.
Recent Accounting Standard Updates	Recent Accounting Standard Updates
	The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or result of its operations.
Reclassification	Reclassification
	The 2014 financial statements have been reclassified to conform to the current year presentation.

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property and Equipment [Abstract]
Summary of property and equipment
			March		December 31,
			31,
			2015		2014
	Autos	$	64,458	$	64,458
	Medical equipment		5,000		5,000
	Other equipment		4,945		4,945
			74,403		74,403
	Less accumulated depreciation		35,442		31,802
		$	38,961	$	42,601

Notes_Payable_and_Long_Term_Lo1

Notes Payable and Long Term Loan (Tables)	3 Months Ended
	Mar. 31, 2015
Notes Payable and Long Term Loan [Abstract]
Schedule of notes payable
			As of
				31-Mar-15			31-Dec-14
	Notes payable at beginning of period		$	1,377,416		$	710,072
	Notes payable issued for cash			212,500			935,500
	Less amounts converted to stock			-295,915			-268,156
	Notes payable at end of period			1,294,001			1,377,416
	Less debt discount			-			-2,391
			$	1,294,001		$	1,375,025
	Notes payable issued to related parties		$	341,000		$	291,000
	Notes payable issued to non-related parties		$	953,001		$	1,086,416
Schedule of future minimum payments
		Twelve months ending,
		31-Mar-16		$	11,764
		31-Mar-17		$	12,121
		31-Mar-18		$	12,488
		31-Mar-19		$	1,064
				$	37,437
		Current portion		$	11,764
		Long term portion		$	25,673

Organization_and_Nature_of_Bus2

Organization and Nature of Business (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Organization and Nature of Business (Textual)
Proceeds from the issuance of notes payable	$212,500	$287,000

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and Equipment Gross	$74,403	$74,403
Less accumulated depreciation	35,442	31,802
Property and Equipment, Net	38,961	42,601
Autos [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment Gross	64,458	64,458
Medical equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment Gross	5,000	5,000
Other equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment Gross	$4,945	$4,945

Notes_Payable_and_Long_Term_Lo2

Notes Payable and Long Term Loan (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Notes Payable and Long Term Loan [Abstract]
Notes payable at beginning of period	$1,377,416	$710,072	$1,377,416
Notes payable issued for cash	212,500	935,500
Less amounts converted to stock	295,915
Notes payable at end of period	1,294,001	1,377,416	1,377,416
Less debt discount		-2,391
Notes payable, Net	1,294,001	1,375,025
Notes payable issued to related parties	341,000	291,000
Notes payable issued to non-related parties	$953,001	$1,084,025

Notes_Payable_and_Long_Term_Lo3

Notes Payable and Long Term Loan (Details 1) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Long term loan, Maturity dates
31-Mar-16	$11,764
31-Mar-17	12,121
31-Mar-18	12,488
31-Mar-19	1,064
Total	37,437
Current portion	11,764	11,677
Long term portion	$25,673	$28,646

Notes_Payable_and_Long_Term_Lo4

Notes Payable and Long Term Loan (Details Textual) (USD $)	1 Months Ended
	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2013	Mar. 31, 2015
Notes Payable and Long Term Loan (Textual)
Aggregate principal amount of promissory notes				$1,158,000
Private Placement [Member]
Notes Payable and Long Term Loan (Textual)
Shares issued in private placement, Value	500,000	500,000	500,000
Issuance of notes payable	$25,000	$25,000	$25,000
Debt instrument interest rate	10.00%	10.00%	10.00%
Common stock shares issued	50,000	50,000	125,000

Shareholders_Deficit_Details

Shareholders' Deficit (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Jun. 30, 2013
Shareholders' Deficit (Textual)
Revaluation of shares based on low trading volume		$0.00
Share issued for services	$2,304
Shares issued with notes payable	325
Conversion into common stock	295,915
Accrued interest	32,223
Common Stock [Member]
Shareholders' Deficit (Textual)
Share issued for services	230
Share issued for service rendered, shares	2,304,286
Shares issued with notes payable	$33
Shares issued with notes payable, shares	325,000
Share issued for conversion of notes payable and accrued interest, shares	12,200,592

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Related Party Transactions (Textual)
Related party advances	$7,755
Due to officer	50,000
Notes payable - related party	$341,000	$291,000

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	1 Months Ended			0 Months Ended	1 Months Ended
	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2013	16-May-15	12-May-15	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Subsequent Event (Textual)
Notes payable						$1,294,001	$1,377,416	$1,377,416	$710,072
Private Placement [Member]
Subsequent Event (Textual)
Issuance of notes payable	25,000	25,000	25,000
Subsequent Event [Member]
Subsequent Event (Textual)
Issuance of shares of restricted common stock					1,695,000
Number of shares outstanding						98,497,026
Shares issued as a part of notes payable				250,000
Notes payable				96,000
Maturity date				15-Aug-15
Subsequent Event [Member] | Private Placement [Member]
Subsequent Event (Textual)
Issuance of shares of restricted common stock					75,000
Issuance of notes payable					37,500
Subsequent Event [Member] | Securities Purchase Agreements [Member]
Subsequent Event (Textual)
Issuance of shares of restricted common stock					43,500